Certara (CERT) to Release Earnings on Tuesday

Certara (NASDAQ:CERT) will be posting its quarterly earnings results after the market closes on Tuesday, May 7th. Analysts expect Certara to post earnings of $0.10 per share for the quarter. Certara has set its FY24 guidance at $0.41-$0.46 EPS and its FY 2024 guidance at 0.410-0.460 EPS.Persons interested in participating in the company’s earnings conference call can do so using this link.

Certara (NASDAQ:CERT) last announced its quarterly earnings data on Thursday, February 29th. The company reported $0.05 earnings per share for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.04). The business had revenue of $88.01 million for the quarter, compared to analyst estimates of $86.80 million. Certara had a positive return on equity of 4.33% and a negative net margin of 15.62%. On average, analysts expect Certara to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Certara Trading Down 0.1 %

NASDAQ:CERT opened at $17.60 on Friday. Certara has a 1 year low of $11.81 and a 1 year high of $23.54. The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.62 and a current ratio of 2.62. The stock has a fifty day moving average price of $17.70 and a two-hundred day moving average price of $16.35. The stock has a market capitalization of $2.82 billion, a price-to-earnings ratio of -50.29, a PEG ratio of 1.82 and a beta of 1.61.

Insiders Place Their Bets

In related news, insider Patrick F. Smith sold 14,427 shares of the business’s stock in a transaction dated Tuesday, April 2nd. The shares were sold at an average price of $16.85, for a total value of $243,094.95. Following the completion of the transaction, the insider now owns 50,091 shares of the company’s stock, valued at approximately $844,033.35. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In other Certara news, SVP Richard M. Traynor sold 3,000 shares of the stock in a transaction on Monday, April 1st. The stock was sold at an average price of $18.00, for a total transaction of $54,000.00. Following the transaction, the senior vice president now owns 173,524 shares of the company’s stock, valued at approximately $3,123,432. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Patrick F. Smith sold 14,427 shares of Certara stock in a transaction on Tuesday, April 2nd. The shares were sold at an average price of $16.85, for a total value of $243,094.95. Following the completion of the sale, the insider now directly owns 50,091 shares of the company’s stock, valued at approximately $844,033.35. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 23,427 shares of company stock valued at $405,095. Corporate insiders own 2.39% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on CERT shares. Leerink Partnrs reiterated a “market perform” rating on shares of Certara in a report on Monday, February 26th. JMP Securities started coverage on shares of Certara in a research report on Thursday, April 4th. They set a “market perform” rating for the company. Barclays upped their price target on Certara from $16.00 to $18.00 and gave the stock an “equal weight” rating in a report on Thursday, January 25th. UBS Group lifted their price objective on Certara from $17.00 to $20.00 and gave the stock a “neutral” rating in a report on Friday, March 1st. Finally, SVB Leerink initiated coverage on Certara in a research report on Monday, February 26th. They set a “market perform” rating and a $19.00 target price on the stock. Seven research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Certara presently has a consensus rating of “Hold” and an average target price of $20.06.

About Certara

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.